We are thrilled to announce the launch of our brand new website: www.luminarygroup.co.uk Luminary Group, is an international executive search and business consultancy specializing in the Life Sciences and Pharmaceutical sectors. Contact us today! #NewWebsite #LuminaryGroup #DigitalLaunch #ExploreNow
About us
Luminary Group is a international business consultancy focused on the life sciences and pharmaceutical sectors. Headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, we deliver comprehensive services in three key areas. Luminary Executive: Specializing in C-suite to Director-level appointments, we identify top talent for positions including Chairman, Board members, CEO, CCO, COO, AVP to Director level. Luminary Staffing: We provide both temporary and permanent staffing solutions tailored to meet the commercial, project management, medical, biometrics, software and operational needs of our clients. Luminary Consulting: Offering high-quality services in medical writing, regulatory affairs, quality assurance, pharmacovigilance, and data science for the medical and pharmaceutical industries. We also provide strategic partnerships to accelerate growth through Recruitment Process Outsourcing (RPO) and Functional Service Provider (FSP) services. Lastly, our advisory services assist in data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe, and provide guidance for business collaborations with biotechnology firms and navigating mergers and acquisitions. Our expertise includes Real World Evidence (RWE), eClinical solutions, Artificial Intelligence (AI), Biotechnology, Consulting, and Medical Devices. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from corporate giants to innovative start-ups. For more information, please visit our website: www.luminarygroup.co.uk.
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
City of London , GB
-
4th St N, STE 300
7901
St. Petersburg, FL , 33702, US
Employees at Luminary Group
Updates
-
𝗜𝗹𝗹𝘂𝗺𝗶𝗻𝗮 𝘄𝗶𝗻𝘀 𝗙𝗗𝗔 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗳𝗼𝗿 𝘁𝗲𝘀𝘁 𝘁𝗼 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝘆 𝘁𝗿𝗲𝗮𝘁𝗮𝗯𝗹𝗲 𝗰𝗮𝗻𝗰𝗲𝗿𝘀 The FDA has approved DNA sequencing giant Illumina cancer test that checks more than 500 genes in a tumor to potentially match patients with targeted … https://lnkd.in/dC3Avw_Q
-
𝗣𝗳𝗶𝘇𝗲𝗿 𝘂𝗻𝘃𝗲𝗶𝗹𝘀 𝗱𝗶𝗿𝗲𝗰𝘁-𝘁𝗼-𝗰𝗼𝗻𝘀𝘂𝗺𝗲𝗿 𝗽𝘂𝘀𝗵 𝗳𝗼𝗿 𝗖𝗼𝘃𝗶𝗱, 𝗳𝗹𝘂 𝗮𝗻𝗱 𝗺𝗶𝗴𝗿𝗮𝗶𝗻𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 Pfizer is expanding its direct-to-patient sales offerings. On Tuesday, the New York pharma launched a new website, called PfizerForAll, that connects patients to clinicians who …Aamir Malik https://lnkd.in/d9VD7BME
Pfizer unveils direct-to-consumer push for Covid, flu and migraine treatments
endpts.com
-
𝗦𝘄𝗶𝘀𝘀 𝗯𝗶𝗼𝘁𝗲𝗰𝗵'𝘀 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿 𝗼𝗳 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗿𝗶𝘃𝗲𝗿 𝘀𝗵𝗼𝘄𝘀 𝗽𝗿𝗼𝗺𝗶𝘀𝗲 𝗶𝗻 𝗿𝗮𝗿𝗲 𝗯𝗹𝗲𝗲𝗱𝗶𝗻𝗴 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿 Vaderis Therapeutics AG announced Tuesday morning that its lead drug candidate, an AKT inhibitor, helped reduce nosebleeds in people with hereditary hemorrhagic telangiectasia, a genetic disorder … https://lnkd.in/eQQiqP3P
Swiss biotech's inhibitor of cancer driver shows promise in rare bleeding disorder
endpts.com
-
𝗠𝗮𝗷𝗼𝗿 𝗚𝗮𝗹𝗮𝗽𝗮𝗴𝗼𝘀 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝘀𝗮𝘆𝘀 𝗶𝘁 𝘄𝗶𝗹𝗹 𝗽𝘂𝘀𝗵 𝗯𝗼𝗮𝗿𝗱 𝗼𝗻 𝗰𝗼𝗺𝗽𝗮𝗻𝘆'𝘀 '𝗽𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲' 𝗮𝗻𝗱 '𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀' One of Galapagos biggest shareholders is taking a more active role in pushing the company’s turnaround. Biotech investment firm EcoR1 Capital, LLC, which owns 9.9% of …Paul Stoffels, MD https://lnkd.in/d8smG68n
Major Galapagos investor says it will push board on company's 'performance' and 'strategic opportunities'
endpts.com
-
𝗠𝘂𝗯𝗮𝗱𝗮𝗹𝗮, 𝗖𝗕𝗖 𝗚𝗿𝗼𝘂𝗽 𝗶𝗻𝗸 $𝟲𝟴𝟬𝗠 𝗱𝗲𝗮𝗹 𝗳𝗼𝗿 𝗨𝗖𝗕’𝘀 𝗻𝗲𝘂𝗿𝗼𝗹𝗼𝗴𝘆 𝗮𝗻𝗱 𝗮𝗹𝗹𝗲𝗿𝗴𝘆 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗶𝗻 𝗖𝗵𝗶𝗻𝗮 ID Phar Belgian Pharmaceuticals UCB is selling parts of its China business to Mubadala and CBC Group for $680 million. In addition to taking over UCB’s mature … https://lnkd.in/d7hn3GKn
Mubadala, CBC Group ink $680M deal for UCB’s neurology and allergy portfolio in China
endpts.com
-
𝗣𝗲𝗽𝘁𝗶𝗱𝗲 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗠𝗕𝗫 𝘀𝘂𝗯𝗺𝗶𝘁𝘀 𝗜𝗣𝗢 𝗽𝗹𝗮𝗻𝘀, 𝗺𝗮𝗸𝗶𝗻𝗴 𝗮 𝘁𝗿𝗶𝗼 𝗼𝗳 𝗽𝗼𝘀𝘁-𝗟𝗮𝗯𝗼𝗿 𝗗𝗮𝘆 𝗡𝗮𝘀𝗱𝗮𝗾 𝗵𝗼𝗽𝗲𝗳𝘂𝗹𝘀 Indiana Biotech and Pharmaceutical Network startup MBX Biosciences, Inc.filed for an initial public offering on Friday night. It became the third clinical-stage drug developer … https://lnkd.in/d5rmjWYd
Peptide biotech MBX submits IPO plans, making a trio of post-Labor Day Nasdaq hopefuls
endpts.com
-
𝗙𝗗𝗔 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝘀 𝗿𝗲𝗳𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗲𝗱 𝗖𝗼𝘃𝗶𝗱 𝗯𝗼𝗼𝘀𝘁𝗲𝗿𝘀 𝗳𝗼𝗿 𝗳𝗮𝗹𝗹 𝘀𝗲𝗮𝘀𝗼𝗻 The FDA cleared a new round of Covid-19 boosters from Moderna and Pfizer that this time target the KP.2 variant. https://lnkd.in/dJ__Fi9T
FDA approves reformulated Covid boosters for fall season
endpts.com
-
𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗕𝗶𝗰𝗮𝗿𝗮 𝘂𝗻𝘃𝗲𝗶𝗹𝘀 𝗜𝗣𝗢 𝗽𝗶𝘁𝗰𝗵 𝘀𝗮𝗺𝗲 𝗱𝗮𝘆 𝗮𝘀 𝗭𝗲𝗻𝗮𝘀 For a while, there were none. Suddenly, there were two. Bicara Therapeutics filed Thursday afternoon for an initial public offering, just …Claire Mazumdar https://lnkd.in/dDKruzmZ
Oncology biotech Bicara unveils IPO pitch same day as Zenas
endpts.com
-
𝗔𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗭𝗲𝗻𝗮𝘀 𝗳𝗶𝗹𝗲𝘀 𝗳𝗼𝗿 𝗜𝗣𝗢 𝗮𝗺𝗶𝗱 𝘀𝘂𝗺𝗺𝗲𝗿 𝗹𝘂𝗹𝗹 𝗳𝗼𝗿 𝗽𝘂𝗯𝗹𝗶𝗰 𝗱𝗲𝗯𝘂𝘁𝘀 Zenas BioPharma filed for an initial public offering on Thursday, marking a rare move for biotech startups this summer. Lonnie Moulder https://lnkd.in/d7iQT2vs
Autoimmune biotech Zenas files for IPO amid summer lull for public debuts
endpts.com